Edition:
United Kingdom

Sierra Oncology Inc (SRRA.OQ)

SRRA.OQ on NASDAQ Stock Exchange Global Market

2.51USD
22 Nov 2017
Change (% chg)

$0.15 (+6.36%)
Prev Close
$2.36
Open
$2.40
Day's High
$2.55
Day's Low
$2.36
Volume
119,177
Avg. Vol
63,785
52-wk High
$2.63
52-wk Low
$1.11

Chart for

About

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response... (more)

Overall

Beta: --
Market Cap(Mil.): $100.36
Shares Outstanding(Mil.): 52.27
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.23 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Sierra Oncology reports net loss $0.19 per share

* Qtrly ‍net loss per share, basic and diluted $0.19​ Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Sierra Oncology appoints Dr. Andrew Allen to board

* Sierra Oncology appoints Dr. Andrew Allen to its board of directors Source text for Eikon: Further company coverage:

25 Oct 2017

BRIEF-Sierra Oncology establishes DNA damage response advisory committee

* ‍sierra Oncology - establishes DNA damage response advisory committee​ Source text for Eikon: Further company coverage:

15 Aug 2017

BRIEF-Sierra Oncology reports qtrly loss per share $‍0.20​

* ‍on track to provide preliminary update from CHK1 inhibitor SRA737 clinical trials in early 2018​

10 Aug 2017

BRIEF-Sierra Oncology granted U.S., EU patents for CHK1 inhibitor SRA737

* Sierra Oncology granted U.S. and EU patents for CHK1 inhibitor SRA737 Source text for Eikon: Further company coverage:

30 May 2017

BRIEF-Sierra Oncology granted U.S, EU patents for Chk1 inhibitor SRA737

* Sierra Oncology granted US and EU patents for Chk1 inhibitor SRA737

30 May 2017

Earnings vs. Estimates